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Summary Cancer chemotherapy interacts with cell proliferation, but data on the relationship between cancer
cell replication and the effect of adjuvant chemotherapy are scarce. We have investigated the S-phase fractions
of the primary tumour from premenopausal breast cancer patients who participated in a randomised trial
comparing 12 cycles of polychemotherapy (CMF) with post-operative radiotherapy. DNA flow cytometry was
performed on frozen tissues from 208 primary breast carcinomas, of which the S-phase fraction was estimated
in 176 cases. There was a significantly higher benefit from CMF among patients with a high S-phase fraction
(P = 0.0033). The relative risk of distant recurrence or death in the chemotherapy group as compared with the
radiotherapy group was 0.19 for patients whose tumours had an S-phase fraction of 10% or over (95% CI
0.07-0.51) and 1.55 (0.88-2.73) for patients whose tumours showed lower S-phase levels. The interaction was
still significant in multivariate analysis (P = 0.0057), including lymph node metastases, tumour size and
oestrogen receptor content. We conclude that the benefit from adjuvant chemotherapy compared with
radiotherapy is largely confined to patients with highly proliferative tumours.
It has become evident that patients with early breast cancer
benefit from adjuvant systemic therapy (Early Breast Cancer
Trialists' Collaborative Group, 1992). Combination chemo-
therapy given at the time of primary treatment can reduce
the risk of death from breast cancer by 25% in young
women. On the other hand, most patients will either remain
disease free without or relapse despite such treatment. An
increasing number of biological factors have been demon-
strated to correlate with prognosis of patients with breast
cancer, but it is still difficult to predict accurately the re-
sponse to treatment.
Cancer chemotherapy interacts with cell proliferation.
Studies concerning treatment of metastatic breast cancer and
preoperative chemotherapy have shown that patients with
highly proliferating breast tumours are more likely to re-
spond to cytotoxic therapy (Sulkes et al., 1979; O'Reilly et
al., 1992; Remvikos et al., 1992; Spyratos et al., 1992). Data
on the relationship between the proliferating activity of the
primary tumour and the effect of adjuvant chemotherapy in
patients with breast cancer are scarce and apparently
conflicting (Bonadonna et al., 1986; Hedley et al., 1987;
O'Reilly et al., 1990; Witzig et al., 1993).
We have therefore analysed retrospectively by DNA flow
cytometry the S-phase fractions of frozen tumour specimens
from premenopausal breast cancer patients who participated
in a large randomised trial comparing 12 cycles of adjuvant
polychemotherapy with post-operative radiotherapy.
Patients and methods
In 1976 the Stockholm Breast Cancer Group initiated a trial
to compare post-operative radiotherapy with adjuvant
chemotherapy (Rutqvist et al., 1989). The trial included pre-
and post-menopausal patients with unilateral, operable breast
cancer. Surgery consisted of modified radical mastectomy.
The patients were required to have either histologically
verified lymph node- metastases or a tumour diameter,
measured on the surgical specimen, exceeding 30 mm. Patient
accrual started in November 1976 and ended in April 1990.
The post-menopausal patients were also included in a con-
current comparison of adjuvant tamoxifen versus no
adjuvant endocrine treatment.
Radiotherapy and chemotherapy
Radiotherapy was given with a high-voltage technique
(Rutqvist et al., 1989). The dose was 46 Gy with 2 Gy per
fraction 5 days a week for total treatment time of about 4.5
weeks. The target volume included the chest wall, axilla,
supraclavicular fossa and internal mammary nodes. The
treatment intent was pursued in 98% of the patients ran-
domised to radiotherapy. The chemotherapy protocol was
the same as in the first Milan trial, that is 12 courses of a
combination of cyclophosphamide, methotrexate and 5-fluor-
ouracil (CMF). In the chemotherapy group, 9% did not
receive the allocated treatment. Among patients who received
at least one course of chemotherapy, there was a large
difference in actual dose levels between the pre- and post-
menopausal groups; only 15% of the post-menopausal
patients received 85% or more of the planned dose compared
with 38% in the premenopausal group.
Follow-up
There was no significant difference in overall survival in any
of the menopausal groups or when all patients were analysed
(Rutqvist et al., 1989). However, post-menopausal patients
randomised to radiotherapy showed a lower incidence of
both distant metastasis (P<0.01) and locoregional recur-
rence (P<0.001). In premenopausal patients, on the other
hand, there was a tendency towards a lower risk of distant
failure in the chemotherapy group (P = 0.08). In a recent
update the difference was statistically significant (unpublished
data).
The present study is restricted to the premenopausal
group. From the 545 premenopausal patients included in the
trial, frozen tumour samples that were spared after hormone
receptor analysis were available in 208 cases. There was no
significant difference in the distribution of lymph node status,
tumour size or oestrogen receptor content comparing the
selected cases with the original series. Eighty-five of the 208
patients had a distant recurrence or died during a median
follow-up period of 8 years.
DNAflow cytometry
A piece of the tumour specimen was minced in citrate buffer
and afterwards a mixture ofchicken and trout red blood cells
was added as internal marker cells. A suspension of isolated
nuclei was prepared without washing steps as described by
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Vindel6v et al. (1983). The procedure included treatment
with a detergent (0.1% NP-40), trypsin and RNAse followed
by filtration through a 41 mm nylon mesh. The suspension
was stained with propidium iodide and measured within 1 h.
In addition, an imprint from the tissues was stained and
examined to ascertain the presence of tumour cells in the
sample. Cell suspensions were analysed with a FACScan flow
cytometer (Becton Dickinson) equipped with a 15 mW argon
laser. The Cellfit software (Becton Dickinson) was used for
data acquisition and 15,000 events were recorded in each
run.
DNA indices (DI) were calculated after zero point adjust-
ment by using the chicken and trout red blood cells as
internal controls. These showed 35% and 80% respectively of
the fluorescence intensity of human (female) diploid cells
stained with propidium iodide. Tumours with a single Go/,
peak were classified as DNA diploid. If an additional peak
was present the tumour was classified as DNA aneuploid.
DNA aneuploid tumours with a DI <1.0 were called DNA
hypodiploid. Small aneuploid populations, with a minimum
of 1,000 cells, were separated from artefacts or diploid G2/M
cells by looking for a corresponding G2/M peak. Median CV
for tumour GO/, peaks was 3.6% with a range between 2.4%
and 7%. For the estimation of S-phase fraction (SPF) a
planimetric method was used, assuming the S-compartment
to have rectangular distribution (Baisch et al., 1975). In order
to minimise the influence of overlapping populations in the
DNA histogram, the height of the rectangle was estimated
from a manually selected area that was judged as represen-
tative. Although the majority of the histograms showed only
slight background debris to the right of the G2/M peak,
background correction was performed according to a base-
line model. By this correction the mean number of histogram
events per channel in an interval to the right of the G2/M
peak was subtracted from that in the S-phase interval. The
SPF was estimated in 176 of the tumours (85%) and ranged
between 0.5% and 35%. The mean S-phase value was 7.1%
and the median was 5.9%.
Statistical methods
The risk of distant recurrence or death in relation to different
variables or interactions between variables was estimated and
tested using Cox's proportional hazards model (Cox, 1972).
The statistical significance of the interaction between S-phase
fraction and treatment was evaluated by treating the S-phase
fraction as a continuous variable in the Cox model, in that
the prespecified S-phase categories, <5%, 5-10% and
> 10%, were coded 1, 2 and 3 respectively. To adjust for the
potentially confounding effects of other variables, e.g.
tumour stage and oestrogen receptor content, we performed
additional Cox analyses in which the model was stratified
according to the other variables. The product-limit method
was used for estimation of cumulative probabilities of distant
disease-free survival (Kaplan & Meier, 1958).
Results
Characteristics of the material are shown in Table I. A high
S-phase fraction was significantly associated with low oest-
rogen receptor content (P<0.0001) and DNA aneuploidy
(P<0.0001), while subgroups categorised by tumour stage
showed no significant difference according to SPF
(P= 0.18).
Using Cox's proportional hazards model, there was a
clearly significant interaction between S-phase fraction and
treatment effect (Table II). The relative risk of distant recur-
rence or death in the chemotherapy group as compared with
the radiotherapy group was 0.19 for patients whose tumours
had an S-phase fraction of 10% and over (95% confidence
interval 0.07-0.51) and 1.55 (0.88-2.73) for patients whose
tumours had an S-phase fraction less than 10%. For patients
with highly proliferating tumours the estimated distant
disease-free survival rate at 5 years was 68% in the CMF
group, while it was 30% in the radiotherapy group (Figure
1). Similar results were obtained when restricting the analysis
to survival (data not shown).
The correlation between S-phase fraction and the outcome
difference between the two treatments was still significant in a
stratified Cox analysis, taking into account possible interac-
tons between treatment and the number of positive lymph
nodes, tumour size and oestrogen receptor (ER) content
(Table III). No other interaction was significant, although
patients with oestrogen receptor negative or large tumours
tended to benefit from chemotherapy. Restricting the analysis
to ER-negative cases showed that those with a high S-phase
fraction still did benefit from adjuvant CMF [relative risk:
SPF >,10%, 0.12 (0.03-0.46); SPF<10%, 1.2 (0.49-2.9)],
and the interaction between treatment and SPF was
Table I S-phase fraction in relation to tumour stage, oestrogen receptor
content and DNA ploidy
S-phase fraction
<5% 5-10% .10% Total
(n = 74) (n =62) (n =40) (n = 176)
Nodal status, tumour size
NO, >30mm 5 (29)a 7 (41) 5 (29) 17 (100)
N+, <20mm 32 (52) 20 (32) 10 (16) 62 (100)
N+, 21-30mm 22 (42) 18 (34) 13 (25) 53 (100)
N+, >30mm 15 (34) 17 (39) 12 (27) 44 (100)
ER content'
<0.1 fmol jg- DNA 16 (25) 23 (36) 25 (39) 64 (100)
)0.1 fmoljg` DNA 58 (53) 37 (34) 14 (13) 109 (100)
DNA ploidy
Diploid 54 (68) 22 (28) 3 (4) 79 (100)
Aneuploid 20 (21) 40 (41) 37 (38) 97 (100)
'Number of patients (%). bData on ER content were missing in three cases.
Table II Relative risk of distant recurrence or death in the chemotherapy group compared
with the radiotherapy group in relation to the S-phase fraction
Number ofpatientsa (%) Relative 95% confidence Test for
SPF (%) Chemotherapy Radiotherapy risk interval trend
<5 37 (14) 37 (11) 1.30 0.59-2.87 X2=8.63
5-10 33 (19) 29 (9) 1.76 0.79-3.88 d.f. = 1
>10 21 (6) 19 (14) 0.19 0.07-0.51 P =0.0033
aNumber of distant recurrences or deaths is shown within parentheses.1260 0. STAL et al.
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Figure I Distant disease-free survival of patients treated with
chemotherapy (CMF) compared with the radiotherapy group
(RT) in relation to the S-phase fraction. Numbers of patients and
distant recurrences or deaths are presented within parentheses.
significant (P = 0.0030). A similar trend was seen for the
ER-positive subgroup.
In the DNA diploid and the DNA aneuploid subgroups,
there was no significant difference in outcome between
patients receiving chemotherapy and radiotherapy (Table
IV). The relative risk comparing the two treatments was not
significantly different for patients having DNA diploid or
aneuploid tumours (P = 0.63). If the tumours were
categorised into DNA hypodiploids (11%) and others, we
found a significant interaction with treatment effect
(P = 0.0012). Among the patients with DNA hypodiploid
tumours, all eight patients receiving radiotherapy relapsed or
died during the follow-up period compared with 5 of 14
patients receiving cytotoxic therapy. Of the DNA hypo-
diploid tumours with assessable S-phase fraction, most
tumours (72%) showed a level of 10% or higher.
Discussion
The results of the present study suggest that the benefit from
adjuvant chemotherapy in premenopausal breast cancer
patients is largely confined to those with highly proliferative
primary tumours. Previously reported evidence for this is
scarce for adjuvant chemotherapy, but the presumption that
rapidly proliferating tumours are more chemosensitive than
others is supported by studies concerning preoperative
chemotherapy and the treatment of metastatic disease. Sulkes
et al. (1979) analysed the response to chemotherapy in 25
women with disseminated breast cancers in relation to the
proliferative activity estimated as the thymidine labelling
index (TLI). The difference in response was strongly cor-
related to TLI. All nine responders showed an LI of 9% or
greater compared with 5 of the 16 who did not respond.
Furthermore, tumour regression in primary breast cancer
observed after preoperative chemotherapy has been signifi-
cantly associated with high S-phase fraction (O'Reilly et al.,
1992; Remvikos et al., 1992; Spyratos et al., 1992), and
repeated cytological sampling during chemotherapy has indi-
cated that tumour regression is parallelled by a decreasing
growth fraction (Skoog et al., 1992).
In trials of adjuvant chemotherapy, the effect of treatment
related to SPF and other factors have been investigated, but
clear conclusions from these reports have not been made.
Hedley et al (1987) were not able to identify a subgroup
defined by DNA flow cytometry in whom adjuvant treatment
was especially beneficial. Witzig et al. (1993) reported that
DNA aneuploidy, but not a high SPF, identified a subgroup
of post-menopausal patients who tended to benefit from
adjuvant chemotherapy. O'Reilly et al. (1990) presented data
on 69 premenopausal patients randomised to receive either
no adjuvant therapy or CMF. The treatment significantly
improved the recurrence-free survival for patients with high
tumour SPF values as well as for patients with low S-phase
Table III Adjusted relative risk of distant recurrence or death in the chemotherapy group compared with the
radiotherapy group in relation to the S-phase fraction, tumour stage and oestrogen receptor status
Number ofpatients' (%) Adjusted 95% confidence Test for
Chemotherapy Radiotherapy relative riskb interval heterogeneity
SPF (%)
<5 37 (14) 37 (11) 1.39 0.60-3.23 X2=7.64c
5-10 32 (18) 28 (9) 1.28 0.52-31.6 d.f. = I
>10 20 (6) 19 (14) 0.21 0.07-0.51 P =0.0057
Tumour stage
NO, > 30 mm 11 (3) 5 (3) 0.21 0.04-1.17
N+, <21mm 26 (11) 36 (11) 1.55 0.66-3.65 X2=4.09
N+ 21-30mm 28 (10) 24 (7) 0.84 0.31-2.29 d.f.=3
N+, >30mm 24 (14) 19 (13) 0.82 0.36-1.86 P =0.25
ER content
(fmoltLg-' DNA)
<0.1 36 (15) 28 (17) 0.63 0.28-1.41 X2=0.71
)0.1 53 (23) 56 (17) 1.00 0.50-2.02 P =0.40
aNumber of distant recurrences or deaths is shown within parentheses. bAdjusted for the other variables listed
in the table. CTest for trend.
Table IV Relative risk of distant recurrence or death in the chemotherapy group compared with the
radiotherapy group in relation to DNA ploidy
Number ofpatientsa (%) Relative 95% confidence Test for
DNA ploidy Chemotherapy Radiotherapy risk interval heterogeneity
Diploid 43 (16) 37 (13) 0.99 0.47-2.08 X= 0.23
Aneuploid 67 (28) 61 (28) 0.78 0.45-1.32 P = 0.63
aNumber of distant recurrences or deaths is shown within parentheses.SPF AND CHEMOTHERAPY OF BREAST CANCER 1261
levels. The same was observed if the patients were divided by
tumour grade, in contrast to the study of Fisher et al. (1983),
who found that a favourable response to adjuvant therapy
was more pronounced in patients with poorly differentiated
tumours. Similar to the present results, however, Bonadonna
et al. (1986) found that the benefit from adjuvant CMF was
largely confined to patients with rapidly proliferating
tumours. In both studies a strong interaction between SPF
and CMF response was seen among ER-negative patients,
suggesting that the mechanism of action of chemotherapy
was cytotoxicity rather than chemical castration, which has
been proposed as a possible mechanism in premenopausal
patients. (Brincker et al., 1987).
Factors other than proliferative activity have been investi-
gated for their possible interaction with response to
chemotherapy. Gusterson et al. (1992) observed a trend
towards less responsiveness in tumours overexpressing the
c-erbB-2 oncogene. In studies of preoperative treatment, a
more favourable response was found if the tumour was
poorly differentiated, oestrogen receptor negative or DNA
aneuploid (Neville et al., 1992; Spyratos et al., 1992). These
factors are known to correlate with S-phase fraction. In the
series of Remvikos et al. (1989), SPF was a better predictor
of tumour responsiveness than tumour grade, hormone
receptor content or DNA ploidy. In line with these results,
we found that S-phase fraction correlated with response
when adjusting for other variables in multivariate analysis.
DNA hypodiploid tumours, which have shown to be associ-
ated with low age (Stal et al., 1992) and poor prognosis
(Ferno et al., 1992) in breast cancer, also seemed to be more
chemosensitive than others. A clear conclusion about an
independent value cannot be made because most of the DNA
hypodiploid tumours showed a high S-phase fraction.
The hypothesis that the proliferative activity of the tumour
might be related to the response to chemotherapy is attrac-
tive, since most cytotoxic agents act specifically against
actively DNA replicating cells. Techniques used to estimate
proliferative activity are, however, associated with methodo-
logical problems. It should be noted that the investigators
who found a significant relation between cell proliferation
and response to treatment used either the thymidine labelling
technique (Sulkes et al., 1979; Bonadonna et al., 1986) or
DNA flow cytometry on fresh or frozen material (Remvikos
et al., 1989; O'Reilly et al., 1992; Spyratos et al., 1992), in
contrast to others who employed paraffin-embedded fixed
tissue (Hedley et al., 1987; O'Reilly et al., 1990; Witzig et al.,
1993). Irrespective of the starting material used, other prob-
lems concern intratumoral heterogeneity and errors related to
the calculation model for SPF. However, although different
models produce different estimated levels of SPF, we and
other investigators have observed that a significant prognos-
tic value is obtained with several models, including the
manual rectangular method (Joensuu et al., 1994; Wingren et
al., 1994). An indirect support for an interaction between
SPF and response to adjuvant chemotherapy was reported
from a study in which all the patients received adjuvant
treatment (Kute et al., 1990). It was found that those with a
tumour of high SPF tended to have a better prognosis in
contrast to the prediction of a high recurrence risk mostly
found in series of systemically untreated patients.
In our study the effect of CMF was compared with that of
post-operative radiotherapy in contrast to trials with
adjuvant chemotherapy in which the control patients received
no adjuvant treatment. Unlike the results obtained for
premenopausal patients by O'Reilly et al. (1990), we found
no benefit from CMF for patients with low S-phase levels,
but rather a trend towards longer distant disease-free survival
in the radiotherapy group. Radiotherapy has long been
regarded as locoregional treatment with little or no effect on
distant recurrence or survival. However, a significant reduc-
tion in distant metastases with adjuvant radiotherapy
compared with surgery alone has been observed among node-
positive patients (Auquier et al., 1992). Although a subse-
quent trial has shown that the risk of distant recurrence in
premenopausal patients is further reduced if radiotherapy is
replaced by CMF (Rutqvist et al., 1989), we cannot exclude
the possibility of a minor benefit from chemotherapy com-
pared with no post-operative treatment among patients
whose tumours show low proliferative activity. Compared
with post-operative radiotherapy, we conclude that the
benefit from adjuvant chemotherapy is largely confined to
patients with highly proliferative primary tumours. In this
view, it is promising that a high proportion of relapses in
systemically untreated premenopausal patients seems to be
identified by S-phase fraction (Stal et al., 1992). Recently, we
also reported results suggesting that SPF is a long-term
prognostic factor in small node-negative tumours (T1NO)
(Stal et al., 1993). These results, together with the present
data, suggest that estimation of proliferative activity could
facilitate the identification of early breast cancer patients
suitable for adjuvant chemotherapy.
This work was supported by grants from the Swedish Cancer
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